Investing.com - Adaptimmune Therapeutics (NASDAQ:ADAP) reported on Friday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.040 on revenue of $7.01M. Analysts polled by Investing.com anticipated EPS of $-0.279 on revenue of $6.3M.
Adaptimmune Therapeutics shares are down 34.93% from the beginning of the year, still down 52.62% from its 52 week high of $5.15 set on November 11, 2021.
Adaptimmune Therapeutics shares gained 9.91% in intra-day trade following the report.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar